Moderna has said it is filing for regulatory approval in the US, and that its vaccine trials have shown no serious safety concerns.
The US-based company has also said its vaccine was 94.1% effective, with 100% efficacy against severe COVID-19 in its phase three trial.
Efficacy was consistent across age, race and ethnicity, as well as gender, the company has said.
Speaking to Reuters news agency, chief medical officer Dr Tal Zaks said: “We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it.”
